%0 Journal Article
%T Three Rounds of External Quality Assessment in France to Evaluate the Performance of 28 Platforms for Multiparametric Molecular Testing in Metastatic Colorectal and Non-Small Cell Lung Cancer
%A Antoinette Lemoine
%A Aude Lamy
%A Bastiaan Tops
%A Caroline Egele
%A Catherine Andrieu
%A Cleo Keppens
%A Clotilde Descarpentries
%A C¨¦cile Aube
%A C¨¦dric Le Marechal
%A Dominique Fetique
%A Elisabeth M.C. Dequeker
%A Etienne Lonchamp
%A Etienne Rouleau
%A Florence Pedeutour
%A Frederique Nowak
%A Frederique Penault-Llorca
%A Han van Krieken
%A H¨¦l¨¨ne Blons
%A Isabelle Soubeyran
%A Jean-Christophe Sabourin
%A Jean-Fran£¿ois C£¿t¨¦
%A Jean-Fran£¿ois Emile
%A Jean-Michel Vignaud
%A Jean-Pierre Bellocq
%A Karen Leroy
%A Laurent Doucet
%A Marjolijn Ligtenberg
%A Nathalie Monhoven
%A Paul Hofman
%A Pierre Laurent-Puig
%A Sofie Delen
%A Val¨¦rie Duranton-Tanneur
%A V¨¦ronique Haddad
%A Yves Denoux
%J The Journal of Molecular Diagnostics
%D 2016
%R 10.1016/j.jmoldx.2015.09.004
%X Personalized medicine has gained increasing importance in clinical oncology, and several
clinically important biomarkers are implemented in routine practice. In an effort
to guarantee high quality of molecular testing in France, three subsequent external
quality assessment rounds were organized at the initiative of the National Cancer
Institute between 2012 and 2014. The schemes included clinically relevant biomarkers
for metastatic colorectal (KRAS, NRAS, BRAF, PIK3CA, microsatellite instability) and
non-small cell lung cancer (EGFR, KRAS, BRAF, PIK3CA, ERBB2), and they represent the
first multigene/multicancer studies throughout Europe.
%U https://jmd.amjpathol.org/article/S1525-1578(15)00263-9/fulltext